glp-1 drugs in development Timeline of discovery and clinical development. (a) Key events GLP-1 Market Industry Trends and

The benefits of these medications for glycaemic control and cardiovascular risk reduction generally outweigh the potential pancreatic risks in appropriately selected patients

Krishnamurthy Clinical Research Coordinator, South Asia A clearly defined documentation pathway and upfront compliance screening supported a structured and transparent internal approval process. R

Common adverse effects include gastrointestinal symptoms such as nausea, vomiting, and diarrhea, which typically diminish over time

However, most formularies cover both Wegovy and Zepbound, so rebates are currently not driving competition, but rather stifling innovative management strategies

Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis

doi: 10.4254/wjh.v7.i10.1297